

Contains Nonbinding Recommendations
Draft – Not for Implementation
Draft Guidance on Eprosartan Mesylate
October 2024

This draft guidance, when finalized, will represent the current thinking of the Food and Drug Administration (FDA, or the Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the Office of Generic Drugs.

In general, FDA's guidance documents do not establish legally enforceable responsibilities. Instead, guidances describe the Agency's current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word *should* in Agency guidances means that something is suggested or recommended, but not required.

Active Ingredient: Eprosartan mesylate

Dosage Form: Tablet

Route: Oral

Strengths: EQ 400 mg Base, EQ 600 mg Base

Recommended Study: One in vivo bioequivalence study with pharmacokinetic endpoints

1. Type of study: Fasting
Design: Single-dose, two-treatment, two-period crossover in vivo
Strength: EQ 600 mg Base
Subjects: Healthy males and non-pregnant, non-lactating females
Additional comments: Females of reproductive potential should use effective contraception during the study.

Analyte to measure: Eprosartan in plasma

Bioequivalence based on (90% CI): Eprosartan

Waiver request of in vivo testing: EQ 400 mg Base based on (i) acceptable bioequivalence study on the EQ 600 mg Base strength, (ii) acceptable in vitro dissolution testing of both strengths, and (iii) proportional similarity of the formulations between both strengths

Dissolution test method and sampling times: The dissolution information for this drug product can be found in the FDA’s Dissolution Methods database, <http://www.accessdata.fda.gov/scripts/cder/dissolution/>. Conduct comparative dissolution testing on 12 dosage units for each of both strengths of the test product and reference listed drug (RLD).¹ Specifications will be determined upon review of the abbreviated new drug application.

Document History: Recommended July 2008; Finalized August 2017; Revised October 2024

Unique Agency Identifier: PSG_020738

¹ If the RLD is not available, refer to the most recent version of the FDA guidance for industry on *Referencing Approved Drug Products in ANDA Submissions*.